Search

Your search keyword '"Clamp, Andrew R."' showing total 229 results
Start Over Author "Clamp, Andrew R."
229 results on '"Clamp, Andrew R."'

2. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Author

Murphy, Alexander D, primary, Porter, Catharine, additional, White, Ann, additional, Irving, Alys, additional, Adams, Richard, additional, Ray, Ruby, additional, Casbard, Angela, additional, Mahmood, Reem D, additional, Karanth, Suman, additional, Zhou, Cong, additional, Pugh, Julia, additional, Wheeler, Chelsey, additional, Roberts, Victoria, additional, Arnetoli, Giorgio, additional, Salih, Zena, additional, Hasan, Jurjees, additional, Mitchell, Claire, additional, Morgan, Robert D, additional, Clamp, Andrew R, additional, and Jayson, Gordon C, additional

Published
2024
Full Text
View/download PDF

5. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

Author

Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Won, O'Donnell, Dearbhaile M, Gallardo-Rincon, Dolores, Blagden, Sarah, Brenton, James, Perren, Tim J, Sundar, Sudha, Lord, Rosemary, Dark, Graham, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Hanna, C Louise, Williams, Sarah, Scatchard, Kate M, Nam, Helena, Essapen, Sharadah, Parkinson, Christine, McAvan, Lucy, Swart, Ann Marie, Popoola, Babasola, Schiavone, Francesca, Badrock, Jonathan, Fananapazir, Fuad, Cook, Adrian D, Parmar, Mahesh, Kaplan, Richard, and Ledermann, Jonathan A

Published
2022
Full Text
View/download PDF

8. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Author

Morgan, Robert D, McNeish, Iain A, Cook, Adrian D, James, Elizabeth C, Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M, Krell, Jonathan, Parkinson, Christine, Poole, Christopher J, Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C, Ledermann, Jonathan A, and Clamp, Andrew R

Published
2021
Full Text
View/download PDF

9. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Author

Colombo, Nicoletta, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Meunier, Juliette, Cameron, Terri, Maloney, Lara, Goble, Sandra, Bedel, Josh, Ledermann, Jonathan A., and Coleman, Robert L.

Published
2020
Full Text
View/download PDF

10. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

Author

Blagden, Sarah P, Cook, Adrian D, Poole, Christopher, Howells, Lesley, McNeish, Ian A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, James, Elizabeth C, White, Ian R, Perren, Timothy, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Kaplan, Richard, Ledermann, Jonathan A, and Clamp, Andrew R

Published
2020
Full Text
View/download PDF

11. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Author

Ledermann, Jonathan A, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Maloney, Lara, Goble, Sandra, and Coleman, Robert L

Published
2020
Full Text
View/download PDF

13. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Published
2020
Full Text
View/download PDF

15. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Author

Banerjee, Susana N, primary, Ring, Kari L, additional, Niewenhuysen, Els Van, additional, Fabbro, Michel, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Colombo, Nicoletta, additional, Santin, Alessandro D, additional, Clamp, Andrew R, additional, Moore, Kathleen N, additional, Rose, Peter G, additional, David M, O’Malley, additional, Chon, Hye Sook, additional, Salinas, Erin A, additional, Prendergast, Emily N, additional, Lustgarten, Stephanie, additional, Rodrigues, Manuel, additional, Gennigens, Christine, additional, Monk, Bradley J, additional, and Grisham, Rachel N, additional

Published
2023
Full Text
View/download PDF

17. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Author

Clamp, Andrew R, Lorusso, Domenica, Oza, Amit M, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, OʼMalley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Goble, Sandra, Coleman, Robert L, and Ledermann, Jonathan A

Published
2021
Full Text
View/download PDF

18. Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

21. Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

22. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma

Author

Banerjee, Susana, primary, Giannone, Gaia, additional, Clamp, Andrew R., additional, Ennis, Darren P., additional, Glasspool, Rosalind M., additional, Herbertson, Rebecca, additional, Krell, Jonathan, additional, Riisnaes, Ruth, additional, Mirza, Hasan B., additional, Cheng, Zhao, additional, McDermott, Jacqueline, additional, Green, Clare, additional, Kristeleit, Rebecca S., additional, George, Angela, additional, Gourley, Charlie, additional, Lewsley, Liz-Anne, additional, Rai, Debbie, additional, Banerji, Udai, additional, Hinsley, Samantha, additional, and McNeish, Iain A., additional

Published
2023
Full Text
View/download PDF

25. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Author

Nelson, Louisa, Tighe, Anthony, Golder, Anya, Littler, Samantha, Bakker, Bjorn, Moralli, Daniela, Murtuza Baker, Syed, Donaldson, Ian J., Spierings, Diana C. J., Wardenaar, René, Neale, Bethanie, Burghel, George J., Winter-Roach, Brett, Edmondson, Richard, Clamp, Andrew R., Jayson, Gordon C., Desai, Sudha, Green, Catherine M., Hayes, Andy, Foijer, Floris, Morgan, Robert D., and Taylor, Stephen S.

Published
2020
Full Text
View/download PDF

27. Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Author

Morgan, Robert D., Burghel, George J., Schlecht, Helene, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C., Woodward, Emma R., and Evans, D. Gareth R.

Subjects
GENETIC mutation, SEQUENCE analysis, SPECIALTY hospitals, DNA, BRCA genes, OVARIAN epithelial cancer, AGE distribution, GENETIC testing, MOLECULAR pathology, CANCER patients, CANCER treatment, STEM cells, DESCRIPTIVE statistics, RESEARCH funding, NUCLEIC acid amplification techniques
Abstract

Simple Summary: Approximately 10–15% of patients with epithelial ovarian cancer have an inherited (germline) BRCA1 or BRCA2 mutation. Following a diagnosis of epithelial ovarian cancer, patients are routinely tested for germline and/or somatic (tumour) BRCA1/2 mutations. Our study shows that if germline BRCA1/2 testing is only performed for patients with a positive tumour BRCA1/2 test result, and tumour testing is performed using Myriad's myChoice® companion diagnostic, a proportion of germline BRCA1/2 large rearrangements could be missed. If paired germline-tumour DNA testing is not possible for all patients, our data shows that it would be appropriate to test all patients with epithelial ovarian cancer aged < 79 years old for germline BRCA1/2 mutations, regardless of the tumour BRCA1/2 result, whilst only needing to test patients aged ≥ 80 years old for a germline BRCA1/2 mutation if they have a positive tumour BRCA1/2 result. Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation sequencing (NGS)-based myChoice® companion diagnostic (CDx; Myriad Genetics, Inc.). Germline BRCA1/2 testing was performed in the North West Genomic Laboratory Hub using NGS and multiplex ligation-dependent probe amplification. Between 11 April 2021 and 11 October 2023, 382 patients were successfully tested for tumour BRCA1 and BRCA2 variants. Of these, 367 (96.1%) patients were tested for germline BRCA1/2 variants. In those patients who underwent tumour and germline testing, 15.3% (56/367) had a BRCA1/2 pathogenic variant (36 germline and 20 somatic). All germline BRCA1/2 pathogenic small sequencing variants were detected in tumour DNA. By contrast, 3 out of 8 germline BRCA1/2 pathogenic large rearrangements were not reported in tumour DNA. The overall concordance of germline BRCA1/2 pathogenic variants detected in germline and tumour DNA was clinically acceptable at 91.7% (33/36). The myChoice® CDx was able to detect most germline BRCA1/2 pathogenic variants in tumour DNA, although a proportion of pathogenic large rearrangements were not reported. If Myriad's myChoice® CDx is used for tumour BRCA1/2 testing, our data supports a testing strategy of germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, with germline BRCA1/2 testing only necessary for patients aged ≥ 80 years old with a tumour BRCA1/2 pathogenic variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Author

Morgan, Robert D, primary, Clamp, Andrew R, additional, Barnes, Bethany M, additional, Timms, Kirsten, additional, Schlecht, Helene, additional, Yarram-Smith, Laura, additional, Wallis, Yvonne, additional, Valganon-Petrizan, Mikel, additional, MacMahon, Suzanne, additional, White, Rhian, additional, Morgan, Sian, additional, McKenna, Sarah, additional, Hudson, Emma, additional, Tookman, Laura, additional, George, Angela, additional, Manchanda, Ranjit, additional, Sundar, Sudha S, additional, Nicum, Shibani, additional, Brenton, James D, additional, Kristeleit, Rebecca S, additional, Banerjee, Susana, additional, McNeish, Iain A, additional, Ledermann, Jonathan A, additional, Taylor, Stephen S, additional, Evans, D Gareth R, additional, and Jayson, Gordon C, additional

Published
2023
Full Text
View/download PDF

31. Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

32. Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Author

Backen, Alison, primary, Renehan, Andrew G., primary, Clamp, Andrew R., primary, Berzuini, Carlo, primary, Zhou, Cong, primary, Oza, Amit, primary, Bannoo, Selina, primary, Scherer, Stefan J., primary, Banks, Rosamonde E., primary, Dive, Caroline, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

33. CCR Translation for the Article from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

35. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., additional, White, Daniel J., additional, Price, Marcus, additional, Burghel, George J., additional, Ryder, W. David J., additional, Mahmood, Reem D., additional, Murphy, Alexander D., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Wheeler, Chelsey, additional, Buckley, Emma, additional, Truelove, Joanna, additional, King, Georgia, additional, Ainaoui, Yasmina, additional, Bhaskar, Sanjeev S., additional, Shaw, Joseph, additional, Evans, D. Gareth R., additional, Kilerci, Bedirhan, additional, Pearce, Simon P., additional, Brady, Gerard, additional, Dive, Caroline, additional, O'Connor, James P.B., additional, Wallace, Andrew J., additional, Rothwell, Dominic G., additional, Edmondson, Richard J., additional, and Jayson, Gordon C., additional

Published
2023
Full Text
View/download PDF

36. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Author

Morgan, Robert D., Burghel, George J., Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Woodward, Emma R., Lalloo, Fiona, Shaw, Joseph, Desai, Sudha, Crosbie, Emma J., Edmondson, Richard J., Schlecht, Helene, Wallace, Andrew J., Jayson, Gordon C., and Evans, Gareth R.

Subjects
BREAST, OVARIAN epithelial cancer, TUMORS, NUCLEOTIDE sequencing, CLINICAL trials, DNA
Published
2023
Full Text
View/download PDF

37. Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

Author

Morgan, Robert D., primary, Burghel, George J., additional, Flaum, Nicola, additional, Bulman, Michael, additional, Smith, Philip, additional, Clamp, Andrew R., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Woodward, Emma R., additional, Lalloo, Fiona, additional, Crosbie, Emma J., additional, Edmondson, Richard J., additional, Schlecht, Helene, additional, Jayson, Gordon C., additional, and Evans, D. Gareth R., additional

Published
2023
Full Text
View/download PDF

38. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Author

O'Malley, David M., primary, Oza, Amit M., additional, Lorusso, Domenica, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Dean, Andrew, additional, Colombo, Nicoletta, additional, Weberpals, Johanne I., additional, Clamp, Andrew R., additional, Scambia, Giovanni, additional, Leary, Alexandra, additional, Holloway, Robert W., additional, Gancedo, Margarita Amenedo, additional, Fong, Peter C., additional, Goh, Jeffrey C., additional, Swisher, Elizabeth M., additional, Maloney, Lara, additional, Goble, Sandra, additional, Lin, Kevin K., additional, Kwan, Tanya, additional, Ledermann, Jonathan A., additional, and Coleman, Robert L., additional

Published
2022
Full Text
View/download PDF

39. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

Author

Coleman, Robert L, primary, Oza, Amit M, additional, Lorusso, Domenica, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Dean, Andrew, additional, Colombo, Nicoletta, additional, Weberpals, Johanne I, additional, Clamp, Andrew R, additional, Scambia, Giovanni, additional, Leary, Alexandra, additional, Holloway, Robert W, additional, Gancedo, Margarita Amenedo, additional, Fong, Peter C, additional, Goh, Jeffrey C, additional, O’Malley, David M, additional, Goble, Sandra, additional, Maloney, Lara, additional, and Ledermann, Jonathan A, additional

Published
2022
Full Text
View/download PDF

42. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer

Author

Morgan, Robert D, primary, Burghel, George J, additional, Flaum, Nicola, additional, Bulman, Michael, additional, Smith, Philip, additional, Clamp, Andrew R, additional, Hasan, Jurjees, additional, Mitchell, Claire, additional, Salih, Zena, additional, Woodward, Emma R, additional, Lalloo, Fiona, additional, Shaw, Joseph, additional, Desai, Sudha, additional, Crosbie, Emma J, additional, Edmondson, Richard J, additional, Schlecht, Helene, additional, Wallace, Andrew J, additional, Jayson, Gordon C, additional, and Evans, D Gareth R, additional

Published
2022
Full Text
View/download PDF

43. Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.

Author

Coleman, Robert L., primary, Oza, Amit M., additional, Lorusso, Domenica, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Dean, Andrew, additional, Colombo, Nicoletta, additional, Weberpals, Johanne I, additional, Clamp, Andrew R., additional, Scambia, Giovanni, additional, Leary, Alexandra, additional, Holloway, Robert W., additional, Amenedo Gancedo, Margarita, additional, Fong, Peter C.C., additional, Goh, Jeffrey C., additional, O'Malley, David M., additional, Goble, Sandra M., additional, Maloney, Lara, additional, and Ledermann, Jonathan A., additional

Published
2022
Full Text
View/download PDF

44. Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.

Author

Pignata, Sandro, primary, Oza, Amit M., additional, Hall, Geoff, additional, Pardo, Beatriz, additional, Madry, Radoslaw, additional, Cibula, David, additional, Klat, Jaroslav, additional, Montes, Ana, additional, Glasspool, Rosalind, additional, Colombo, Nicoletta, additional, Pete, Imre, additional, Herrero, Ana, additional, Romeo, Marga, additional, Ilieva, Rumyana Nedyalkova, additional, Timcheva, Constanta, additional, Di Maio, Massimo, additional, Barnicle, Alan, additional, Taylor, Rosemary, additional, Bashir, Zahid, additional, and Clamp, Andrew R., additional

Published
2022
Full Text
View/download PDF

45. Additional file 1 of c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

Author

Morgan, Robert D., Ferreras, Cristina, Peset, Isabel, Avizienyte, Egle, Renehan, Andrew G., Edmondson, Richard J., Murphy, Alexander D., Nicum, Shibani, Van Brussel, Thomas, Clamp, Andrew R., Lambrechts, Diether, Zhou, Cong, and Jayson, Gordon C.

Subjects
integumentary system, embryonic structures, cardiovascular system
Abstract

Additional file 1: Figure S1- Examples of tissue microarray immunofluorescence staining for VEGFR-2 and c-MET. Figure S2- Progression-free survival for VEGF-A rs3025033 and VEGFR-2 rs1870377 SNPs in the control (chemotherapy) and experimental (chemotherapy plus bevacizumab) group. Figure S3- Summary of findings for c-MET/VEGFR-2 co-localisation and SNP VEGFR-2 rs2305945.

Published
2022
Full Text
View/download PDF

46. Additional file 2 of c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

Author

Morgan, Robert D., Ferreras, Cristina, Peset, Isabel, Avizienyte, Egle, Renehan, Andrew G., Edmondson, Richard J., Murphy, Alexander D., Nicum, Shibani, Van Brussel, Thomas, Clamp, Andrew R., Lambrechts, Diether, Zhou, Cong, and Jayson, Gordon C.

Subjects
integumentary system, embryonic structures, cardiovascular system
Abstract

Additional file 2: Table S1- Characteristics of immunofluorescence biomarkers and their association with demographic data. Table S2- Prognostic and predictive biomarkers assessed as significant in the univariable analysis. Table S3- List of the 35 SNPs in VEGF-A and VEGFR-2 tested and their association with c-MET/VEGFR-2 co-localisation. Table S4- Frequency of three key SNPs in VEGF-related genes. Table S5- Relationship between c-MET/VEGFR-2 co-localisation and VEGFR-2 rs2305945 SNP.

Published
2022
Full Text
View/download PDF

49. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial

Author

Banerjee, Susana N., primary, Tang, Monica, additional, O'Connell, Rachel L., additional, Sjoquist, Katrin, additional, Clamp, Andrew R., additional, Millan, David, additional, Nottley, Steven, additional, Lord, Rosemary, additional, Mullassery, Vinod Menon, additional, Hall, Marcia, additional, Gourley, Charlie, additional, Bonaventura, Tony, additional, Goh, Jeffrey C., additional, Sykes, Peter, additional, Grant, Peter T., additional, McNally, Orla, additional, Alexander, Laura, additional, Kelly, Caroline, additional, Carty, Karen, additional, Divers, Laura, additional, Bradshaw, N., additional, Edmondson, Richard J., additional, and Friedlander, Michael, additional

Published
2021
Full Text
View/download PDF

50. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Author

Oaknin, Ana, primary, Oza, Amit M., additional, Lorusso, Domenica, additional, Aghajanian, Carol, additional, Dean, Andrew, additional, Colombo, Nicoletta, additional, Weberpals, Johanne I., additional, Clamp, Andrew R., additional, Scambia, Giovanni, additional, Leary, Alexandra, additional, Holloway, Robert W., additional, Amenedo Gancedo, Margarita, additional, Fong, Peter C., additional, Goh, Jeffrey C., additional, O’Malley, David M., additional, Armstrong, Deborah K., additional, Banerjee, Susana, additional, García‐Donas, Jesus, additional, Swisher, Elizabeth M., additional, Cameron, Terri, additional, Maloney, Lara, additional, Goble, Sandra, additional, Ledermann, Jonathan A., additional, and Coleman, Robert L., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results